Genetic susceptibility to fixed drug eruption: evidence for a link with HLA-B22.
BACKGROUND
Our observation of familial cases of fixed drug eruption (FDE) prompted us to consider a genetic predisposition to this disease.


OBJECTIVE
Our purpose was to determine whether there is any association between FDE and any of the major histocompatibility complex class I or II alleles.


METHODS
HLA class I and II typing was performed by lymphocytotoxicity assay in 36 unrelated patients with FDE.


RESULTS
Significantly higher (p < 0.0001) frequencies of the B22 and Cw1 antigens were found in the 36 patients with FDE.


CONCLUSIONS
Our data are the first to suggest a genetic predisposition to FDE.
Pellicano
R
R
Department of Dermatology, IRCCS, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.
Ciavarella
G
G
Lomuto
M
M
Di Giorgio
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004198:Disease Susceptibility; D003875:Drug Eruptions / Q000235:genetics*; D005190:Family; D005260:Female; D011298:Feprazone / Q000009:adverse effects; D015235:HLA-B Antigens / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D012882:Skin Tests
D015235:HLA-B Antigens; D011298:Feprazone